| http://www.w3.org/ns/prov#value | - Cytokinetics, Incorporated intends to use the net proceeds from this offering and our concurrent common stock and warrants offering to fund the conduct of a Phase IIb clinical trial for our drug candidate CK-2017357, to fund other research and development activities, and for other general corporate purposes, including working capital.
|
